Theriva Biologics, Inc. TOVX
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Theriva Biologics, Inc. (TOVX) is a healthcare company listed in the US with a market value of about $7M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -69%.
About Theriva Biologics
Theriva Biologics is listed in the US and classified in biotechnology: pharmaceutical preparations. It was profitable in 0 of the last 10 years in our data. Its share count rose by 1880% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Net income | -$25M | -$26M | -$18M | -$20M | -$14M | -$10M | -$15M | -$13M | -$15M | -$27M |
| Free cash flow | -$17M | -$17M | -$19M | -$19M | -$13M | -$12M | -$14M | -$17M | -$20M | -$28M |
| EPS (diluted) | $-0.52 | $-4.76 | $-7.12 | $-8.19 | $-11.87 | $-41.25 | $-61.25 | $-70.00 | $35.00 | $-1.25 |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| ROIC | -105.8% | -128.1% | -50.4% | -37.6% | -21.3% | — | -486.6% | -81.3% | — | -806.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 1 analysts is $4.00, 2676% above the current price; targets range from $4.00 to $4.00; the consensus rating is “none”; expected EPS is $-0.25 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Theriva Biologics pay a dividend?
Not currently.
Is Theriva Biologics a good stock to buy?
We do not give buy or sell advice. Theriva Biologics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.